AHCO stock sentiment todayAdaptHealth Corp.
Sentiment verdict
Gossip first, financials second — COLD at 65% confidence.
Last updated · cached analysis, refreshes periodically
AHCO
AdaptHealth Corp.A heavily indebted roll-up story struggling with stagnant organic growth and significant executive turnover.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for AHCO. Not financial advice.
Price · last 12 months
Gossip
The narrative is dominated by skepticism over the 'roll-up' business model, leadership instability (multiple CEO changes), and the overhang of a potential GLP-1 impact on sleep apnea equipment demand.
- ·Short interest remains elevated due to reimbursement concerns
- ·Doubts about long-term CPAP demand vs. GLP-1 weight loss drugs
- ·Executive suite revolving door eroding investor trust
Financial
While revenue remains stable, the balance sheet is burdened by over $2B in debt and significant goodwill, leaving little room for error as interest rates remain high.
- ·Net Debt/EBITDA ratio exceeds 3.5x
- ·P/E ratio (forward) appears low (~6x) but reflects high leverage risk
- ·Negative net income in recent fiscal years due to heavy impairment charges
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·Insiders bought a net $395K on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Medicare reimbursement rate cuts for HME (Home Medical Equipment)
- ·Interest rate sensitivity on variable-rate debt portions
- ·Competitive pressure from integrated health systems
Peer temperature
How direct competitors stack up against AHCO right now.
- HOTRMDResMed Inc.
HOTTER — Dominant hardware manufacturer with superior margins and a clear software-as-a-service growth tailwind.
See full analysis → - NEUTRALOMCLOmnicell, Inc.
WARMER — While also struggling with macro headwinds, they offer a more defensible tech-driven pharmacy automation moat.
See full analysis → - COLDOWLTOwlet, Inc.
COLDER — Higher risk micro-cap profile with less diversified revenue streams and higher volatility than AHCO.
See full analysis →
- AHCO+3.0%
- RMD+4.0%
- OMCL+7.6%
- OWLT-23.0%
Analyst price target
Consensus average of 5 analysts · median 10.00
Source: StockAnalysis.com · updated 2026-09-17
AI-generated analysis for informational purposes only. Not financial advice.